About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Evaluation of the QuantiFERON-TB Test. | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02256839

Evaluation of the QuantiFERON-TB Test.

To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.

Lead sponsor: QIAGEN Gaithersburg, Inc•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

QIAGEN Gaithersburg, Inc

To compare the specificity of the CST001 assay to the QFT Gold Test in low TB exposure risk subjects and non-tuberculosis mycobacterial infections.

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Low-exposure Risk Group
•No identified risk factors for TB infection
•history of nontuberculous mycobacterial disease (pulmonary or extrapulmonary) in accordance with the 2007 ATS/IDSA criteria

Exclusion Criteria

•Age less than 18 years or greater than 80 years
•Identified Risk Factors For TB Infection
•Non-tuberculous mycobacterial infection Group
•Age less than 18 years or greater than 80 years
•Identified Risk Factors For TB Infection

Related studies

Training Protocol on the Natural History of Tuberculosis

NCT01212003 · Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, and more

An Adaptive Randomized Controlled Trial

NCT05633056 · Multi Drug Resistant Tuberculosis, HIV Infections

Rapid Research in Diagnostics Development for TB Network

NCT04923958 · Tuberculosis

RECRUITINGPhase 2/3

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029 · Latent Tuberculosis

Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

NCT06590428 · Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 1, 2019Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment268

Start dateOct 2014

Last updatedAug 1, 2019

Condition

Locations shown

Oregon Health & Sciences University

Portland, Oregon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 1, 2019Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions